X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic

By Guest Contributor  |    June 24, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

In combating COVID-19, science is how we get back to normal

By Lori Reilly  |    June 24, 2020
America’s biopharmaceutical companies are working around the clock to combat a common enemy: COVID-19. As the fight to research and develop innovative treatments and vaccines advances, I’m pleased...   Read More

Guest Post: What will we learn from COVID-19?

By Guest Contributor  |    May 27, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines

By Stephen J. Ubl  |    April 15, 2020
As biopharmaceutical companies continue to fight COVID-19 through research and development, three companies have created programs empowering employees with medical or laboratory expertise to...   Read More

To the millions affected by COVID-19

By Stephen J. Ubl and Giovanni Caforio, M.D.  |    April 9, 2020
In these unprecedented times, it can be hard to feel optimistic, but there are reasons to stay positive. The Food and Drug Administration has expedited approval of diagnostic tests. Hospitals and...   Read More

Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19

By Andrew Powaleny  |    April 6, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for...   Read More

The biopharmaceutical industry’s unique role in responding to COVID-19

By Richard Moscicki, M.D.  |    April 2, 2020
As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States and around the globe, both the private and public sectors are working around the clock...   Read More

ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus

By Gabby Migliara  |    April 1, 2020
Recently, PhRMA hosted a teleconference to provide an update on our member companies’ around-the-clock efforts in developing treatments and vaccines for COVID-19, a disease caused by a novel...   Read More

COVID-19 Response: Supporting the frontline

By Stephen J. Ubl  |    March 30, 2020
Updated 7/13/2020 In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of...   Read More

Guest post: Looking out for the invisibly vulnerable in the time of COVID-19

By Guest Contributor  |    March 26, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

Subscribe to Email Updates